A Study of Neladalkib (NVL-655)
Phase 1/2
840
about 5.6 years
12+
21 sites in CA, CO, DC +14
About this study
Researchers are testing a treatment called neladalkib (NVL-655) in people with advanced lung cancer and other solid tumors that have ALK rearrangements or activating ALK mutations. The trial will evaluate the safety, tolerability, and effectiveness of this treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Neladalkib (NVL-655)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 1), Objective Response Rate (ORR) (Phase 2)
Secondary: Clinical benefit rate (CBR), Duration of response (DOR), Half-life (t1/2) of neladalkib (NVL-655), Maximum plasma concentration, (Cmax) of neladalkib (NVL-655), Number of participants with treatment-emergent adverse events, as assessed by CTCAE, V5.0 (Phase 2), Objective response rate (ORR) (Phase 1), Oral clearance (CL/F) of neladalkib (NVL-655), Overall survival (OS) (Phase 2)
Oncology